nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

01.04.2015 | Editorial

When is chemotherapy in head and neck squamous cell carcinoma not indicated?

verfasst von: Missak Haigentz Jr., Jan B. Vermorken, Arlene A. Forastiere, June Corry, Jonathan J. Beitler, Primož Strojan, Dana M. Hartl, Juan P. Rodrigo, Carol R. Bradford, Alessandra Rinaldo, Robert P. Takes, William M. Mendenhall, Ashok R. Shaha, Gregory T. Wolf, Alfio Ferlito

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Excerpt

Given the widespread availability of several effective multidisciplinary care plans, the decision-making and clinical management for the patient with head and neck squamous cell carcinoma (HNSCC) are complicated. Although national guidelines like the National Comprehensive Cancer Network (NCCN) guidelines in the United States exist for patient care by disease site and stage of disease [1], the choice of therapeutic approach for a particular patient should be based on goals of care, patient functional status and comorbidities, and morbidities associated with treatment. The goals of HNSCC therapy can be categorized as either curative, employing either surgery and/or radiotherapy as a therapeutic backbone, or palliative, where symptom management and maintenance or improvement of quantity and quality of life are the primary focus. …

National Comprehensive Cancer Network (NCCN) Guidelines, Head and Neck Cancers, Version 2.2013

Pignon JP, le Maître A, Maillard E, Bourhis J, MACH-NC Collaborative Group (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92:4–14CrossRefPubMed

Bourhis J, Overgaard J, Audry H et al (2006) Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 368:843–854CrossRefPubMed

Beitler JJ, Zhang Q, Fu KK et al. Final results of local-regional control and late toxicity of RTOG 90-03; a randomized trial of altered fractionation radiation for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys (in press)

Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35CrossRefPubMedCentralPubMed

Bourhis J, Sire C, Graff P et al (2012) Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 13:145–153CrossRefPubMed

Overgaard J, Hansen HS, Specht L et al (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362:933–940CrossRefPubMed

Overgaard J, Mohanti BK, Begum N et al (2010) Five versus six fractions of radiotherapy per week for squamous-cell carcinoma of the head and neck (IAEA-ACC study): a randomised, multicentre trial. Lancet Oncol 11:553–560CrossRefPubMed

Haigentz M Jr, Corry J, Strojan P, Ferlito A (2012) Easing acceleration of head and neck chemoradiotherapy. Lancet Oncol 13:113–115CrossRefPubMed

10.

Liang ZG, Zhu XD, Zhou ZR, Qu S, Du YQ, Jiang YM (2012) Comparison of concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis of 793 patients from 5 randomized controlled trials. Asian Pac J Cancer Prev 13:5747–5752CrossRefPubMed

11.

Holsinger FC, Kies MS, Diaz EM Jr et al (2009) Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 27:1976–1982CrossRefPubMedCentralPubMed

12.

Holsinger FC, Lin HY, Bassot V, Laccourreye O (2009) Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer 115:3909–3918CrossRefPubMed

13.

Divi V, Worden FP, Prince ME et al (2010) Chemotherapy alone for organ preservation in advanced laryngeal cancer. Head Neck 32:1040–1047CrossRefPubMedCentralPubMed

14.

Forastiere AA, Shaha AR (2009) Chemotherapy alone for laryngeal preservation, is it possible? J Clin Oncol 27:1933–1934CrossRefPubMed

15.

Haigentz M Jr, Silver CE, Rinaldo A, Ferlito A (2010) Definitive chemotherapy: a new frontier in the fight against laryngeal cancer. Eur Arch Otorhinolaryngol 267:1–4CrossRefPubMed

16.

Robbins KT, Kumar P, Harris J et al (2005) Supradose intra-arterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol 23:1447–1454CrossRefPubMed

17.

Nomura K, Takahara M, Katayama A et al (2013) Intra-arterial cisplatin with concomitant radiation for advanced hypopharyngeal cancer. Laryngoscope 123:916–922CrossRefPubMed

18.

Kovács AF (2006) Response to intraarterial induction chemotherapy: a prognostic parameter in oral and oropharyngeal cancer. Head Neck 28:678–688CrossRefPubMed

19.

Regine WF, Valentino J, Arnold SM et al (2001) High-dose intra-arterial cisplatin boost with hyperfractionated radiation therapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 19:3333–3339PubMed

20.

Spring PM, Valentino J, Arnold SM et al (2005) Long-term results of hyperfractionated radiation and high-dose intraarterial cisplatin for unresectable oropharyngeal carcinoma. Cancer 104:1765–1771CrossRefPubMed

21.

Rasch CR, Hauptmann M, Schornagel J et al (2010) Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a randomized phase 3 trial. Cancer 116:2159–2165CrossRefPubMed

22.

Ackerstaff AH, Rasch CR, Balm AJ et al (2012) Five-year quality of life results of the randomized clinical phase III (RADPLAT) trial, comparing concomitant intra-arterial versus intravenous chemoradiotherapy in locally advanced head and neck cancer. Head Neck 34:974–980CrossRefPubMed

23.

Janot F, de Raucourt D, Benhamou E et al (2008) Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 26:5518–5523CrossRefPubMed

24.

Choe KS, Haraf DJ, Solanki A et al (2011) Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer 117:4671–4678CrossRefPubMed

25.

Strojan P, Corry J, Eisbruch A et al (2014) Recurrent and second primary squamous cell carcinoma of the head and neck: When and how to re-irradiate. Head Neck. doi:10.1002/hed.23542

26.

Gugic J, Strojan P (2013) Squamous cell carcinoma of the head and neck in the elderly. Rep Pract Oncol Radiother 18:16–25CrossRefPubMedCentral

27.

Bonner JA, Harari PM, Giralt J et al (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11:21–28CrossRefPubMed

28.

Haigentz M Jr, Cohen EE, Wolf GT, Strojan P, Eisbruch A, Ferlito A (2012) The future of induction chemotherapy for head and neck squamous cell carcinoma. Oral Oncol 48:1065–1067CrossRefPubMed

29.

Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14:257–264CrossRefPubMed

30.

Hitt R, Grau JJ, López-Pousa A et al (2014) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer. Ann Oncol 25:216–225CrossRefPubMed

31.

Cohen EEW, Karrison T, Kocherginsky M et al (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30:5500

32.

Argiris A, Li Y, Forastiere A (2004) Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101:2222–2229CrossRefPubMed

33.

Argiris A, Ghebremichael M, Gilbert J et al (2013) Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 31:1405–1414CrossRefPubMedCentralPubMed

34.

Shiels MS, Pfeiffer RM, Gail MH et al (2011) Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 103:753–762CrossRefPubMedCentralPubMed

35.

Haigentz M Jr (2005) Aerodigestive cancers in HIV infection. Curr Opin Oncol 17:474–478CrossRefPubMed

36.

McLemore MS, Haigentz M Jr, Smith RV et al (2010) Head and neck squamous cell carcinomas in HIV-positive patients: a preliminary investigation of viral associations. Head Neck Pathol 4:97–105CrossRefPubMedCentralPubMed

37.

Haigentz M Jr, Jung G, Garg M, Owen R, Schiff B, Smith RV (2006) Squamous cell carcinoma of the head and neck (SCCHN) in patients reporting human immunodeficiency virus (HIV) infection: a retrospective case series. J Clin Oncol 24:5570

38.

Klein EA, Guiou M, Farwell DG et al (2011) Primary radiation therapy for head-and-neck cancer in the setting of human immunodeficiency virus. Int J Radiat Oncol Biol Phys 79:60–64CrossRefPubMed

39.

Persad GC, Little RF, Grady C (2008) Including persons with HIV infection in cancer clinical trials. J Clin Oncol 26:1027–1032CrossRefPubMed

40.

Weiss SA, Gajavelli S, Negassa A, Sparano JA, Haigentz M (2011) Evaluation of cancer trial eligibility criteria (with focus on non-AIDS-defining cancers) for inclusion of persons with HIV infection. J Clin Oncol 29:6092CrossRef

41.

Ang KK, Zhang QE, Rosenthal DI et al (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 29:5500

42.

Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116–1127CrossRefPubMed

43.

Vermorken JB, Trigo J, Hitt R et al (2007) Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171–2177CrossRefPubMed

44.

Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269CrossRefPubMed

45.

Haigentz M Jr, Silver CE, Corry J et al (2009) Current trends in initial management of oropharyngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 266:1845–1855CrossRefPubMed

Titel: When is chemotherapy in head and neck squamous cell carcinoma not indicated?
verfasst von: Missak Haigentz Jr.
Jan B. Vermorken
Arlene A. Forastiere
June Corry
Jonathan J. Beitler
Primož Strojan
Dana M. Hartl
Juan P. Rodrigo
Carol R. Bradford
Alessandra Rinaldo
Robert P. Takes
William M. Mendenhall
Ashok R. Shaha
Gregory T. Wolf
Alfio Ferlito
Publikationsdatum: 01.04.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 4/2015
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-014-2894-9

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

When is chemotherapy in head and neck squamous cell carcinoma not indicated?

Excerpt

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2015

Salivary mucoepidermoid carcinoma revisited

Endoscopic Ho laser interstitial therapy for pharyngolaryngeal venous malformations in adults

Tonsillotomy: facts and fiction

Applications of titanium mesh tubing in external ear canal reconstruction in congenital aural atresia

Comment to the article “Open partial horizontal laryngectomies: a proposal for classification by the working committee on nomenclature of the European Laryngological Society” by G. Succo et al.

Cochlear obliteration after translabyrinthine vestibular schwannoma surgery

Neu im Fachgebiet HNO

Kinder mit anhaltender Sinusitis profitieren häufig von Antibiotika

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

Sind Frauen die fähigeren Ärzte?

Akuter Schwindel: Wann lohnt sich eine MRT?

Update HNO